Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Stephens Investment Conference on November 16, 2020, at 1:00 p.m. ET. A live audio webcast of the presentation, along with the slide presentation, will be accessible on the investor section of Teleflex's website. Teleflex is dedicated to enhancing healthcare through innovative medical technologies across various fields, including vascular access, anesthesia, and respiratory care.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share of common stock. This dividend will be paid on December 15, 2020 to shareholders recorded as of November 15, 2020. Teleflex is committed to providing medical technologies that enhance the health and quality of life of patients. The company focuses on innovation to meet clinical needs across diverse fields including vascular access, urology, and emergency medicine. For more details, visit teleflex.com.
Teleflex reported third quarter 2020 revenues of $628.3 million, a decline of 3.1% year-over-year. GAAP diluted EPS was $2.46, down 49.3% from $4.85 in the previous year. Adjusted EPS fell 6.7% to $2.77. Revenue was adversely affected by the COVID-19 pandemic, with an estimated $78 million impact, contributing to a 12% revenue loss. Despite these challenges, growth was noted in the Interventional Urology sector and Vascular Access products. The company announced an acquisition of Z-Medica, LLC, expected to enhance earnings per share in 2021.
Teleflex Incorporated (NYSE: TFX) has entered a definitive agreement to acquire Z-Medica, LLC for $500 million plus potential performance bonuses of $25 million. The acquisition, aimed at enhancing Teleflex's portfolio in hemostatic products, is expected to close in Q4 2020, pending regulatory approvals. Z-Medica's innovative products, including QuikClot and Combat Gauze, are poised to boost Teleflex's revenue by $60-$70 million in fiscal 2021 and enhance earnings per share. The deal aligns with Teleflex's strategy to invest in high-growth medical technologies.
Teleflex (NYSE: TFX) expands its UroLift portfolio with the new UroLift Advanced Tissue Control (ATC) System, aimed at enhancing treatment for benign prostatic hyperplasia (BPH). Cleared by the FDA in June 2020, the UroLift ATC System offers advancements in treating complex prostate anatomies, allowing urologists to more effectively manage obstructive median lobes and large lateral lobes. Early feedback from urologists indicates satisfaction with its usability and effectiveness. The UroLift System has shown significant positive outcomes in patient symptoms and quality of life, establishing its credibility in the market.
Teleflex Incorporated has launched the Arrow® ErgoPack® Complete CVC System, marking a significant update in more than a decade. This system is designed after extensive research with vascular access professionals and includes features such as the Arrow GlideWheel™ Advancer for improved control and a kink-resistant nitinol guidewire. With a focus on reducing CLABSI, the system complies with major health guidelines. Teleflex's Arrowg+ard Blue Plus® CVC is the only full-spectrum antimicrobial catheter addressing key pathogens linked to CLABSI, which causes up to 28,000 deaths annually in the U.S.
Teleflex Incorporated (NYSE: TFX) is set to release its third-quarter 2020 financial results before the market opens on October 29, 2020. An investor conference call will follow at 8:00 a.m. ET. Interested parties can access the live audio webcast on the company’s website. The replay of the call will be available from November 29, 2020, until November 3, 2020. Teleflex is dedicated to improving health through medical technologies across various fields, including vascular access and surgical care.
Teleflex Incorporated (NYSE: TFX) has received 510(k) clearance from the U.S. FDA to extend the indications for use of the Arrow® EZ-IO® Intraosseous Vascular Access System. This device can now be utilized for up to 48 hours when traditional intravenous access is challenging. The expansion is particularly vital for patients requiring long-term access during emergencies.
According to Corporate Vice President Michelle Fox, this advancement aims to enhance patient care during times of resource constraints.
NeoTract, a subsidiary of Teleflex (NYSE: TFX), has recognized Dr. Erik Alexander from Arizona Urology Specialists as a UroLift® Center of Excellence for his expertise in treating Benign Prostatic Hyperplasia (BPH) with the UroLift System. This FDA-cleared, minimally invasive procedure offers an effective treatment for BPH symptoms without surgical side effects. Over 40 million men in the U.S. suffer from BPH, and the UroLift System has treated over 100,000 patients, providing durable symptom relief and improved quality of life.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
